Agnès Guerci‐Bresler

Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia

Gabriel Étienne, Joëlle Guilhot, Delphine Réa et al. · Journal of Clinical Oncology · 2016 · 484 citations

Hematological Malignancy, Stop Imatinib, Chronic Myeloid Leukemia +14

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

Pierre Fenaux, Aristoteles Giagounidis, Dominik Selleslag et al. · Blood · 2011 · 475 citations · Full text

Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease

Philippe Rousselot, Aude Charbonnier, Pascale Cony‐Makhoul et al. · Journal of Clinical Oncology · 2013 · 405 citations · Full text

Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia

Claude Preudhomme, Joëlle Guilhot, Franck E. Nicolini et al. · New England Journal of Medicine · 2010 · 382 citations

Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study

Delphine Réa, Franck E. Nicolini, Michel Tulliez et al. · Blood · 2016 · 314 citations · Full text